LENZ insider purchase: 10,500 shares acquired at $22.7884

Q: What insider transaction did LENZ (LENZ) report?

A Director purchased 10,500 shares of common stock on 11/07/2025 .

Q: What was the purchase price in the LENZ insider trade?

The weighted-average purchase price was $22.7884 per share, across a range of $22.68 to $22.87 .

Q: How many LENZ shares does the insider own after the trade?

Post-transaction holdings are 10,500 shares directly and 620,599 shares indirectly by trust.

Q: Does the LENZ filing mention any transfers to a trust?

Yes. Indirect holdings include 95,034 shares transferred to the McCollum Living Trust on June 6, 2024 .

Q: What was the transaction code in the LENZ Form 4?

The transaction was coded P , indicating a purchase of common stock.

Q: What is the insider’s relationship to LENZ?

The reporting person is a Director of LENZ Therapeutics, Inc.

Filing Impact

(Moderate)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

LENZ Therapeutics disclosed an insider purchase. A Director bought 10,500 shares of common stock on 11/07/2025 at a weighted-average price of $22.7884. After the transaction, the Director beneficially owns 10,500 shares directly and 620,599 shares indirectly through a trust. The indirect holdings include 95,034 shares transferred to the McCollum Living Trust on June 6, 2024.

Insider Trade Summary

Net Buyer: 10,500 shares ($239,278)

Net Buy 2 txns

Insider MCCOLLUM JAMES W

Role Director

Bought 10,500 shs ($239K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,500	$22.7884	$239K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 10,500 shares (Direct); Common Stock — 620,599 shares (Indirect, By trust)

Footnotes (1)

Represents the weighted average share price of an aggregate total of 10,500 shares purchased in the price range of $22.68 to $22.87 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Includes 95,034 shares transferred by the Reporting Person to the McCollum Living Trust on June 6, 2024.

Form 4 Insider Transactions: What Each Field Means →

11/10/2025 - 04:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCOLLUM JAMES W

(Last)

(First)

(Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE, SUITE 300

(Street)

SOLANA BEACH

92075

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/07/2025		P		10,500	A	$22.7884⁽¹⁾	10,500	D
Common Stock								620,599⁽²⁾	I	By trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the weighted average share price of an aggregate total of 10,500 shares purchased in the price range of $22.68 to $22.87 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

2. Includes 95,034 shares transferred by the Reporting Person to the McCollum Living Trust on June 6, 2024.

Remarks:

	/s/ Daniel R. Chevallard, as Attorney-in-Fact	11/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did LENZ (LENZ) report?

A Director purchased 10,500 shares of common stock on 11/07/2025.

What was the purchase price in the LENZ insider trade?

The weighted-average purchase price was $22.7884 per share, across a range of $22.68 to $22.87.

How many LENZ shares does the insider own after the trade?

Post-transaction holdings are 10,500 shares directly and 620,599 shares indirectly by trust.

Does the LENZ filing mention any transfers to a trust?

Yes. Indirect holdings include 95,034 shares transferred to the McCollum Living Trust on June 6, 2024.

What was the transaction code in the LENZ Form 4?

The transaction was coded P, indicating a purchase of common stock.

What is the insider’s relationship to LENZ?

The reporting person is a Director of LENZ Therapeutics, Inc.